Progesterone receptor modulates ERα action in breast cancer

Nature

Volumn 523, Issue 7560, 2015, Pages 313-317

  Mohammed, Hisham ^a   Russell, I Alasdair ^a   Stark, Rory ^a   Rueda, Oscar M ^a   Hickey, Theresa E ^b   Tarulli, Gerard A ^b   Serandour, Aurelien A A ^a   Birrell, Stephen N ^b   Bruna, Alejandra ^a   Saadi, Amel ^a   Menon, Suraj ^a   Hadfield, James ^a   Pugh, Michelle ^a   Raj, Ganesh V ^c   Brown, Gordon D ^a   D'Santos, Clive ^a   Robinson, Jessica L L ^a   Silva, Grace ^d   Launchbury, Rosalind ^a   Perou, Charles M ^d   Stingl, John ^a   Caldas, Carlos ^a,e,f   Tilley, Wayne D ^b   Carroll, Jason S ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PROGESTERONE; PROGESTERONE RECEPTOR; CHROMATIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA, HUMAN; LIGAND; PROTEIN BINDING;

BIOMARKER; CANCER; ESTROGENIC COMPOUND; GENE EXPRESSION; LIGAND; PROTEIN; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL LINE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; COPY NUMBER VARIATION; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HORMONAL THERAPY; HORMONE SUBSTITUTION; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MICE; PROGESTERONE; PROTEIN BINDING; RECEPTORS, PROGESTERONE; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937557662     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14583     Document Type: Article

References (44)

1. Chlebowski, R. T. et al. Estrogen plus progestin and breast cancer incidence and mortalityinpostmenopausal women. J. Am. Med. Assoc. 304, 1684-1692 (2010).
2. Bentel, J. M. et al. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol. Cell. Endocrinol. 154, 11-20 (1999).
3. Fournier, A., Berrino, F. & Clavel-Chapelon, F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 107, 103-111 (2008).
4. Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
5. Vignon, F., Bardon, S., Chalbos, D. & Rochefort, H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56, 1124-1130 (1983).
6. Musgrove, E. A., Swarbrick, A., Lee, C. S., Cornish, A. L. & Sutherland, R. L. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18, 1812-1825 (1998).
7. Chen, C. C., Hardy, D. B. & Mendelson, C. R. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1). J. Biol. Chem. 286, 43091-43102 (2011).
8. Kabos, P. et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res. Treat. 135, 415-432 (2012).
9. Zheng, Z. Y., Bay, B. H., Aw, S. E. & Lin, V. C. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. J. Biol. Chem. 280, 17480-17487 (2005).
10. Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K. & Clark, G. M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapyin two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979 (2003).
11. Pichon, M. F., Pallud, C., Brunet, M. & Milgrom, E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 40, 3357-3360 (1980).
12. Badwe, R. et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J. Clin. Oncol. 29, 2845-2851 (2011).
13. Bines, J. et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann. Oncol. 25, 831-836 (2014).
14. Lee, Y. J. & Gorski, J. Estrogen-induced transcription of the progesterone receptor gene does not parallel estrogen receptor occupancy. Proc. Natl Acad. Sci. USA 93, 15180-15184 (1996).
15. Dowsett, M. et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 23, 7512-7517 (2005).
16. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
17. Viale, G. et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 25, 3846-3852 (2007).
18. Cui, X., Schiff, R., Arpino, G., Osborne, C. K. & Lee, A. V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23, 7721-7735 (2005).
19. Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genet. 43, 27-33 (2011).
20. Read, L. D., Snider, C. E., Miller, J.S., Greene, G. L. & Katzenellenbogen, B. S. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol. Endocrinol. 2, 263-271 (1988).
21. Mohammed, H. et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 3, 342-349 (2013).
22. Ballaré, C. et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol. Cell. Biol. 23, 1994-2008 (2003).
23. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
24. Stark, R. & Brown, G. D. DiffBind: differential binding analysis of ChIP-Seq peak data. Bioconductor http://bioconductor.org/packages/release/bioc/html/DiffBind.html (2011).
25. Clarke, C. L. & Graham, J. D. Non-overlapping progesterone receptor cistromes contribute tocell-specific transcriptional outcomes. PLoS ONE 7, e35859 (2012).
26. Liang, Y., Besch-Williford, C., Brekken, R. A. & Hyder, S. M. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 67, 9929-9936 (2007).
27. Centenera, M. M. et al. Evidence for efficacy ofnew Hsp90 inhibitors revealedby ex vivo culture of human prostate tumors. Clin. Cancer Res. 18, 3562-3570 (2012).
28. Dean, J. L. et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11, 2756-2761 (2012).
29. Curtis, C. et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
30. Tomlinson, I. P., Nicolai, H., Solomon, E. & Bodmer, W. F. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J. Pathol. 180, 38-43 (1996).
31. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404 (2012).
32. Schmidt, D. et al. ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009).
33. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
34. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
35. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
36. Venet, D., Dumont, J.E. & Detours, V. Most random gene expressionsignatures are significantly associated with breast cancer outcome. PLOS Comput. Biol. 7, e1002240 (2011).
37. Stark, R. & Norden, J. Checking gene expression signatures against random and known signatures with SigCheck. Bioconductor http://www.bioconductor.org/packages/release/bioc/html/SigCheck.html.
38. Tilley, W. D. et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res. 54, 4096-4102 (1994).
39. Bengtsson, H., Wirapati, P. & Speed, T. P. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 25, 2149-2156 (2009).
40. Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657-663 (2007).
41. Dunning, M. J., Smith, M. L., Ritchie, M. E. & Tavare, S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183-2184 (2007).
42. Cairns, J. M., Dunning, M. J., Ritchie, M. E., Russell, R. & Lynch, A. G. BASH:a tool for managing BeadArray spatial artefacts. Bioinformatics 24, 2921-2922 (2008).
43. Barbosa-Morais, N. L. et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 38, e17 (2010).
44. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).